Neoadjuvant Hormonal Therapy Before Radical Prostatectomy: Favorable Pathological and PSA Outcomes Do Not Guarantee Favorable Oncological Outcomes.
BACKGROUND To evaluate the impact of neoadjuvant hormonal therapy (Neo-HT) on postoperative pathological and prostate-specific antigen (PSA) outcomes after radical prostatectomy (RP) and oncological outcomes in patients with favorable postoperative outcomes (pT0-2N0, negative surgical margin and undetectable PSA). ME...